SUN.NS
Latest Trade
427.00INRChange
-1.60(-0.37%)Volume
4,959,765Today's Range
-
434.6052 Week Range
-
484.25As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 428.60 |
|---|---|
Open | 431.85 |
Volume | 4,959,765 |
3M AVG Volume | 122.65 |
Today's High | 434.60 |
Today's Low | 423.60 |
52 Week High | 484.25 |
52 Week Low | 344.55 |
Shares Out (MIL) | 2,399.30 |
Market Cap (MIL) | 1,028,355.00 |
Forward P/E | 22.65 |
Dividend (Yield %) | 0.63 |
FDA Approves First Generics Of Gilenya
India's Sun Pharma Says Considering Appeal In U.S. Court Ruling
India's Sun Pharma Reports Profit In Sept Qtr
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
Industry
Biotechnology & Drugs
Executive Leadership
Israel Makov
Non-Executive Chairman of the Board
C. S. Muralidharan
Chief Financial Officer
Dilip Shantilal Shanghvi
Managing Director, Executive Director
Sailesh T. Desai
Whole-time Director
Kalyanasundaram Subramanian
Whole Time Director
Price To Earnings (TTM) | 23.76 |
|---|---|
Price To Sales (TTM) | 3.27 |
Price To Book (MRQ) | 2.37 |
Price To Cash Flow (TTM) | 15.33 |
Total Debt To Equity (MRQ) | 17.22 |
LT Debt To Equity (MRQ) | 4.92 |
Return on Investment (TTM) | 10.72 |
Return on Equity (TTM) | 7.14 |
Top Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday Britain's AstraZeneca would distribute some of Sun's cancer treatment drugs in China, the world's second-largest pharmaceutical market.
Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday it would introduce some of its cancer treatment drugs in China through Britain's AstraZeneca.
* Nifty PSU bank index ends down 0.83%; SBI among top decliners
India's largest drugmaker by market value Sun Pharmaceutical Industries Ltd posted a nearly four-fold jump in quarterly profit on Tuesday, breezing past estimates on strong sales in the U.S. market.
Sun Pharmaceutical Industries Ltd , India's largest drugmaker by market value, posted a nearly four-fold jump in quarterly profit on Tuesday, beating estimates.
* Shares jump over 6 pct (Adds analyst comments, updates share move)
Indian drugmaker Sun Pharmaceutical Industries Ltd said https://www.nseindia.com/corporate/SUNPHARMA456_22012019083723_IntimationSE20190122_001.pdf on Tuesday it will make its unit the new distributor for its domestic formulations business, replacing Aditya Medisales.
Shares of Sun Pharmaceutical Industries Ltd <SUN.NS> plunged 13 percent on Friday to near six-year lows, hit by reports that a whistleblower filed a complaint to regulators over transactions involving the top Indian drugmaker and its co-promotor.
Sun Pharmaceutical Industries Ltd <SUN.NS> on Friday asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company's shares.
Sun Pharmaceutical Industries Ltd on Friday asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company's shares.
Shares of India's Sun Pharmaceutical Industries Ltd slumped over 13 percent on Friday to near six-year low, after a media report of a complaint by a whistleblower raised fresh concerns on the drugmaker's corporate governance.
Indian shares hit a one-week closing low on Wednesday after the country's central bank left interest rates unchanged, while resurgent trade worries dented global sentiment.
Shares of India's Sun Pharmaceutical Industries sank more than 10 percent on Monday after a report of a regulatory probe against the country's biggest drug manufacturer by market value.
Sun Pharmaceutical Industries Ltd on Monday said it has reached settlements resolving claims that a company it acquired had illegally accepted payments from Cephalon Inc to delay the release of a generic version of its wakefulness drug Provigil.
Sun Pharmaceutical Industries was sent to an unexpected second-quarter loss by a one-off charge for an antitrust litigation settlement.
Sun Pharmaceutical Industries Ltd , India's largest drugmaker by market capitalisation, posted a surprise quarterly loss on Tuesday, hurt by a one-time charge due to a legal settlement.
* Stock top gainer on NSE index (Adds details on U.S. and India sales, share movement)
India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a first-quarter profit on Tuesday, beating street estimates.
India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) cleared its Halol drug plant, which had been under supply restrictions due to quality control failures.
Indian shares ended higher for a third session on Monday, as lower crude prices and a firmer rupee lifted sentiment, with financial and oil stocks accounting for much of the gains.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.